It leads with exercise in a pill because AMPK manipulation is broadly expected to be a path towards an exercise mimetic. Go do some background reading on AMPK a

It leads with exercise in a pill because AMPK manipulation is broadly expected to be a path towards an exercise mimetic. Go do some background reading on AMPK and related proteins and pathways and their effects on longevity and health in lower animals. What I find annoying about this reporting is that it is being spun as a success when by all measures it is a failure. It is a failure in exactly the same way sirtuin research was a failure, in that it only appears to produce benefits in metabolically abnormal individuals, and even then they are not high quality benefits. Meaning it isn't at all what was aimed for: the researchers have failed in even their original modest goals of slightly slowing aging by recapitulating the broad effects of exercise. Of course you can still make a profit selling very marginal treatments for type 2 diabetes to people who have that condition because they are obese and thus metabolically abnormal. This is a condition that can actually be reversed right up until very late stages by dietary restriction ( http://dx.doi.org/10.2337/db11-1835 http://dx.doi.org/10.2337/db11-1835, http://www.bbc.com/news/health-13887909 http://www.bbc.com/news/health-13887909 ), for all that few people appear to either know or be willing to act on that knowledge. The sort of therapies that might result from AMPK manipulation would be terrible in comparison to the outcome of just eating less. But that has nothing to do with making real progress in medicine. Medical research in general is so very vulnerable to disruption: you have entrenched groups producing terrible products at massive cost under heavy regulation in the midst of a revolution in the underlying technologies and plummeting costs of creating new knowledge and therapies. Something has to give.